Biotechnology & Medical Research

Page 1

ZS Pharma Inc presents new data from ZS003 two week phase 3 Trial demonstrating that ZS-9 prevented recurrence of hyperkalemia in heart failure patients on RAASi

6:30pm EDT

ZS Pharma Inc:Announces results of secondary analysis of ZS003, two week pivotal Phase 3 trial of ZS-9 (sodium zirconium cyclosilicate), its investigational treatment for hyperkalemia.Hyperkalemia is a life-threatening condition characterized by higher than normal levels of potassium (K+) in blood serum.Analysis showed that once-daily dosing of ZS-9 prevented recurrence of hyperkalemia in patients with heart failure taking stable dose of renin angiotensin aldosterone system (RAAS) inhibitor therapy.Secondary analysis was conducted to determine if once-daily dosing of ZS-9 could prevent recurrence of hyperkalemia relative to placebo in those patients with heart failure who were currently using RAASi therapy.Secondary analysis included 147 normokalemic heart failure patients, all of whom were on RAASi therapy, had recent hyperkalemia, and who were randomized to once-daily dosing of ZS-9 or placebo. RAASi therapy was kept constant in all patients.Heart failure patients on RAASi who received either 5g or 10g of once-daily ZS-9 maintained mean K+ levels in the normal range throughout the 12 day treatment period with mean K+ of 4.7 and 4.5 mEq/L for 5g and 10g doses respectively.

Ultragenyx announces positive results from long-term phase 1/2 study of KRN23 in adult patients with X-Linked Hypophosphatemia

9:00am EDT

Ultragenyx Pharmaceutical Inc:Says results from long-term Phase 1/2 extension study, conducted by Kyowa Hakko Kirin Pharma, Inc., of investigational fully human anti-FGF23 monoclonal antibody KRN23 (UX023) in adult patients with X-linked hypophosphatemia (XLH).The cumulative 16-month data, combining four-month dose escalation period data from INT-001 and the 12-month extension data from INT-002, were presented at American Society of Bone and Mineral Research (ASBMR) Annual Meeting in Houston.Ultragenyx and Kyowa Hakko Kirin Co., Ltd. (Tokyo:4151) initiated Phase 2 study of KRN23 in pediatric patients in US and EU in June 2014 and expect to continue the clinical development of KRN23 in adults with XLH.

Inovio Pharmaceuticals begins trading on NASDAQ Global Select Market Exchange

8:59am EDT

Inovio Pharmaceuticals Inc:Met the stringent listing criteria for the NASDAQ Global Select Market and has transferred to this U.S. stock exchange from the NYSE MKT.Company will continue to trade under its current ticker symbol, "INO.".

Avanir Pharmaceuticals Inc announces positive phase II trial results

8:30am EDT

Avanir Pharmaceuticals Inc:Says positive results from its phase II clinical trial evaluating the safety and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease.Treatment with AVP-923 was associated with significantly reduced agitation as measured by the primary endpoint, the agitation/aggression domain score of the neuropsychiatric inventory (NPI) compared to placebo (p=0.00008).The reduction in agitation was observed in both stage 1 (p=0.0002) and stage 2 (p=0.021) of the Sequential Parallel Comparison study design.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.